Skip to main content

Table 1 Patients’ profiles and cytotoxicity of T cells expressing anti-CD19- or anti-CD38-CAR against primary DHL cells

From: T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Cells

Karyotype (major abnormalities)

IHC-positive

FISH-positive

aExpression of CD38 in CD19+ cells (%)

aSpecific cytotoxicity of anti-CD19-CAR T cells (%)

aSpecific cytotoxicity of anti-CD38-CAR T cells (%)

Patient 1

t(8;22)(q24;q11.2),t(14;18)(q32;q21)

BCL2

MYC: ND

BCL2 MYC

98.69 ± 0.37

92.67 ± 0.55

97.49 ± 0.19

Patient 2

add(8)(q24),t(8;14)(q24;q32), t(3;22)(q27;q11.2)

BCL2

BCL6

MYC

BCL6

MYC

98.74 ± 0.59

95.53 ± 2.88

99.88 ± 0.73

Patient 3

ND

BCL2

BCL6

MYC

BCL6

97.37 ± 0.02

98.94 ± 0.03

99.60 ± 0.27

Patient 4

ND

BCL2

MYC: ND

BCL2

MYC

98.47 ± 0.26

98.26 ± 0.78

99.47 ± 0.04

Patient 5

+8,add(3)(q27)

BCL2

BCL6

MYC

BCL6

97.14 ± 0.83

97.41 ± 0.16

97.70 ± 0.23

  1. Specific cytotoxicity was evaluated by flow cytometry following the co-incubation of T cells bearing anti-CD19- or anti-CD38-CAR (E) with DHL cells (T) at an E:T ratio of 1:2 for 3 days. The cutoffs for positivity for BCL2, BCL6, or MYC were 50, 30, and 40% of the cells, respectively
  2. ND not determined
  3. aResults are the mean ± SD of three experiments